<DOC>
	<DOC>NCT00093210</DOC>
	<brief_summary>The primary objective of this clinical research study is to establish the bioequivalence of 2 treatments, rFIX and rFIX-R, when given as a 10-minute intravenous bolus infusion.</brief_summary>
	<brief_title>Study Evaluating of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R) in Moderate to Severe Hemophilia B</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>Moderate to severe hemophilia B (FIX: C ≤2%) Previously treated patients (PTPs) with ≥150 documented exposure days Age ≥ 12 years (US sites only) Detectable factor IX inhibitor defined as ≥0.6 Bethesda Units for pooled plasma reported by the local laboratory (family history of inhibitors will not exclude the patient) Patient history of factor IX inhibitor replacement therapy Patient unable to be off factor IX replacement therapy for at least 5 days without bleeding</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>